Get the Stockscreener App
14.77
1.07%
-0.16
Rapport Therapeutics Inc stock is traded at $14.77, with a volume of 182.18K.
It is down -1.07% in the last 24 hours and down -2.83% over the past month.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
See More
Previous Close:
$14.93
Open:
$15.05
24h Volume:
182.18K
Relative Volume:
1.02
Market Cap:
$539.07M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.44%
1M Performance:
-2.83%
6M Performance:
+16.48%
1Y Performance:
-30.36%
1-Day Range:
$14.73
$15.71
1-Week Range:
$13.86
$15.71
52-Week Range:
$7.13
$29.74
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
99 HIGH STREET, BOSTON
Compare RAPP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
14.77 | 532.50M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Apr-08-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
Rapport Therapeutics Inc Stock (RAPP) Latest News
Can Rapport Therapeutics Inc. hit a new high this monthQuarterly Portfolio Review & Low Volatility Stock Suggestions - Newser
Real time breakdown of Rapport Therapeutics Inc. stock performanceTrade Signal Summary & Short-Term High Return Strategies - Newser
Is Now a Good Time to Reenter Rapport Therapeutics Inc.July 2025 Earnings & Free Weekly Chart Analysis and Trade Guides - thegnnews.com
Rapport Therapeutics Inc. stock prediction for this weekQuarterly Profit Report & Real-Time Volume Analysis Alerts - Newser
Published on: 2025-08-20 00:39:25 - Newser
What MACD and RSI say about Rapport Therapeutics Inc.Weekly Risk Summary & Smart Allocation Stock Reports - Newser
Ranking Rapport Therapeutics Inc. among high performing stocks via toolsJuly 2025 Spike Watch & Daily Market Momentum Tracking - Newser
Intraday pattern recognizer results for Rapport Therapeutics Inc.Watch List & Consistent Growth Equity Picks - Newser
Published on: 2025-08-19 14:52:10 - Newser
What Fibonacci levels say about Rapport Therapeutics Inc. reboundEarnings Recap Summary & Short-Term Swing Trade Alerts - Newser
Market reaction to Rapport Therapeutics Inc.’s recent news2025 Stock Rankings & Daily Stock Momentum Reports - Newser
Chart based exit strategy for Rapport Therapeutics Inc.Weekly Trading Summary & Community Driven Trade Alerts - Newser
How to manage a losing position in Rapport Therapeutics Inc.July 2025 Retail & Risk Managed Investment Signals - Newser
Why Rapport Therapeutics Inc. stock attracts strong analyst attentionInsider Buying & Smart Allocation Stock Reports - thegnnews.com
Will Rapport Therapeutics Inc. rebound enough to break evenJuly 2025 Gainers & Precise Buy Zone Identification - Newser
What data driven models say about Rapport Therapeutics Inc.’s futureMarket Movers & Safe Entry Trade Reports - Newser
How hedge fund analytics apply to Rapport Therapeutics Inc. stockMarket Growth Summary & High Accuracy Trade Signal Alerts - Newser
Published on: 2025-08-15 16:33:54 - Newser
Rapport Therapeutics Inc.’s volatility index tracking explainedQuarterly Trade Report & Daily Stock Trend Reports - Newser
Rapport Therapeutics Inc. Shows Support at Fibonacci LevelMarket Rally & Consistent Return Strategy Ideas - newsyoung.net
JonesTrading Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $42 - 富途牛牛
XTX Topco Ltd Buys Shares of 15,442 Rapport Therapeutics, Inc. (NASDAQ:RAPP) - Defense World
Q3 EPS Forecast for Rapport Therapeutics Cut by Analyst - Defense World
Comparing Rapport Therapeutics Inc. in custom built stock radarsInflation Watch & Low Drawdown Investment Ideas - Newser
Published on: 2025-08-12 06:02:16 - Newser
Analysts Conflicted on These NA Names: Core Scientific Inc (CORZ) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
What momentum shifts mean for Rapport Therapeutics Inc.Reversal Signal Prediction Based on Volume - Newser
Rapport Therapeutics Inc Stock (RAPP) Financials Data
There is no financial data for Rapport Therapeutics Inc (RAPP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Rapport Therapeutics Inc Stock (RAPP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bredt David | Chief Scientific Officer |
Jul 15 '25 |
Sale |
14.00 |
8,500 |
118,962 |
435,142 |
| Bredt David | Chief Scientific Officer |
Jun 16 '25 |
Sale |
11.00 |
8,500 |
93,522 |
443,642 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):